Bright Minds Biosciences (XCNQ:DRUG) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bright Minds Biosciences's EBITDA for the three months ended in Dec. 2023 was C$-1.68 Mil. Bright Minds Biosciences's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, Bright Minds Biosciences's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Bright Minds Biosciences EBITDA Margin % Historical Data

The historical data trend for Bright Minds Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences EBITDA Margin % Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

EBITDA Margin %

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Bright Minds Biosciences's EBITDA Margin %

For the Biotechnology subindustry, Bright Minds Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's EBITDA Margin % falls into.

Bright Minds Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bright Minds Biosciences's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-7.314	/	0
	=	%

Bright Minds Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.681	/	0
	=	%

Bright Minds Biosciences (XCNQ:DRUG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bright Minds Biosciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (XCNQ:DRUG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.